Sinoviortesis con radioisótopos
en hemofilia: Experiencia de un centro
en Chile
Author
dc.contributor.author
Soto, Verónica
Author
dc.contributor.author
Morales, María Mercedes
Author
dc.contributor.author
Morales, Patricio
Author
dc.contributor.author
Oyarzún, Andrés
Author
dc.contributor.author
Cortez, Daniela
Author
dc.contributor.author
González, Macarena
Admission date
dc.date.accessioned
2019-10-14T15:41:01Z
Available date
dc.date.available
2019-10-14T15:41:01Z
Publication date
dc.date.issued
2019
Cita de ítem
dc.identifier.citation
Revista Médica de Chile, Volumen 147, Issue 5, 2019, Pages 568-573
Identifier
dc.identifier.issn
07176163
Identifier
dc.identifier.issn
00349887
Identifier
dc.identifier.other
10.4067/S0034-98872019000500568
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/171509
Abstract
dc.description.abstract
Background: In patients with hemophilia, radionuclide synoviorthesis, or the
intra-articular injection of a radionuclide to decrease the synovial hypertrophy
tissue, aims to decrease or avoid hemarthrosis. Aim: To evaluate the effectiveness
of radionuclide synoviorthesis in hemophilia. Material and Methods: Observational
retrospective study of the evolution of 107 male patients aged 3 to 54
years who were subjected to radionuclide synoviorthesis between 2007 and 2015.
Results: Of 164 treated joints, in 65% treatment was successful, (defined as zero
to two hemarthroses and absence of synovitis during the follow up period), in 17%
it was partially successful (defined as two or less hemarthroses, but persistence of
the synovitis) and failed in 18% of the procedures. No important complications
were recorded. Conclusions: Radionuclide synoviorthesis has an overall 82%
success rate, is minimally invasive, can be used at any age and is inexpensive
We recommend its implementation in Chilean hemophilia treatment centers.